Search This Blog

Thursday, April 30, 2026

NovoCure non-GAAP EPS $-0.62 (-100%) miss, revenue $174.1M (+12%) beat, ups revenue guidance

 

NovoCure Q1 2026 results: non-GAAP EPS $-0.62 (-100%) misses, revenue $174.1M (+12%) beats, raises 2026 revenue guidance to $690M-$710M

  • Company also raised 2026 adjusted EBITDA guidance alongside the updated 2026 revenue outlook.
  • NovoCure disclosed its Q1 2026 financial results in a filing with the SEC.
  • Company highlighted recent FDA approval and launch of its Optune Pax therapy in the quarterly update.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)